Jefferies Financial Group Inc. Takes Position in Eyepoint Pharmaceuticals, Inc. $EYPT

Jefferies Financial Group Inc. bought a new position in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 140,000 shares of the company’s stock, valued at approximately $1,994,000.

A number of other hedge funds have also made changes to their positions in EYPT. State of Alaska Department of Revenue bought a new position in Eyepoint Pharmaceuticals during the 3rd quarter valued at about $50,000. Tower Research Capital LLC TRC grew its stake in Eyepoint Pharmaceuticals by 218.3% during the second quarter. Tower Research Capital LLC TRC now owns 8,700 shares of the company’s stock worth $82,000 after buying an additional 5,967 shares during the last quarter. Raymond James Financial Inc. grew its stake in Eyepoint Pharmaceuticals by 11.0% during the second quarter. Raymond James Financial Inc. now owns 11,900 shares of the company’s stock worth $112,000 after buying an additional 1,177 shares during the last quarter. New York State Common Retirement Fund increased its holdings in shares of Eyepoint Pharmaceuticals by 17.3% during the third quarter. New York State Common Retirement Fund now owns 12,214 shares of the company’s stock worth $174,000 after buying an additional 1,800 shares in the last quarter. Finally, Fox Run Management L.L.C. bought a new position in shares of Eyepoint Pharmaceuticals in the third quarter valued at approximately $185,000. Institutional investors and hedge funds own 99.41% of the company’s stock.

Analyst Ratings Changes

EYPT has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Thursday, January 22nd. HC Wainwright raised their price target on Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Citigroup lifted their price objective on Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Monday. Cantor Fitzgerald raised Eyepoint Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, November 25th. Finally, TD Cowen upgraded Eyepoint Pharmaceuticals to a “strong-buy” rating in a report on Friday, December 19th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $32.20.

Insider Activity at Eyepoint Pharmaceuticals

In other news, insider Ramiro Ribeiro sold 42,544 shares of the business’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $17.10, for a total transaction of $727,502.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 4.46% of the company’s stock.

Eyepoint Pharmaceuticals Trading Down 3.4%

Shares of EYPT stock opened at $14.92 on Thursday. Eyepoint Pharmaceuticals, Inc. has a 1 year low of $3.91 and a 1 year high of $19.11. The firm’s 50 day moving average is $15.49 and its 200-day moving average is $14.45. The firm has a market capitalization of $1.24 billion, a price-to-earnings ratio of -4.72 and a beta of 1.72.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings results on Wednesday, March 4th. The company reported ($0.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.03). Eyepoint Pharmaceuticals had a negative net margin of 739.39% and a negative return on equity of 88.31%. The company had revenue of $0.62 million during the quarter, compared to analyst estimates of $1.01 million. On average, equities research analysts forecast that Eyepoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

Eyepoint Pharmaceuticals Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.